Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SCOLR starts studies

This article was originally published in The Tan Sheet

Executive Summary

SCOLR Pharma announces Nov. 1 the start of the first of three trials to evaluate the safety and efficacy of its OTC 12-hour CDT-based ibuprofen. The Bellevue, Wash.-based firm expects to complete the trials of its controlled delivery technology ibuprofen by the end of the first quarter of 2008, and plans to file a new drug application in the second half of 2008...

You may also be interested in...



SCOLR’s sales and earnings

SCOLR Pharma's net revenues in its fiscal 2007 declined 13 percent to $2 million, the Bellevue, Wash.-based firm says in a March 11 release. Royalty income related to SCOLR's alliance with Perrigo increased 38 percent to $1.2 million in 2007, however, the gain was offset by a decrease in research and development revenue associated with the termination of an agreement with Wyeth Consumer Healthcare, the firm notes. SCOLR's net loss for the year was $10.6 million compared to $10.7 million in 2006. Achievements in 2007 include the completion of two of three product performance trials to evaluate the safety and efficacy of OTC 12-hour ibuprofen with controlled delivery technology (1"The Tan Sheet" Nov. 5, 2007, In Brief). The third trial is slated for completion by the end of the second quarter this year, and the firm plans to submit its new drug application for the product in the second half of the year...

Biocon And Mylan's Fulphila And Insulin Plans On Track

Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.

Pharma Has High Hopes Of Pilot On Simultaneous Advice From EU Countries

Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers. 

Topics

UsernamePublicRestriction

Register

PS101078

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel